Results 231 to 240 of about 128,009 (300)

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

open access: yes
American Journal of Hematology, EarlyView.
Kenneth I. Ataga   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy